To date, at least 11 FGFR1 fusion partners have been identified, most of which induce a myeloproliferative neoplasm or disorder (MPN/MPD) and lymphadenopathy, usually involving T-lymphoblastic lymphoma/leukemia predominantly of an immature T-cell type. This evidence concerns the gene FGFR1 and myeloproliferative disorder.